Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 47, Issue 4, 2012, Pages 581-588

  Johnston, L ^a   Florek, M ^a   Armstrong, R ^b   McCune, J S ^a   Arai, S ^a   Brown, J ^a   Laport, G ^a   Lowsky, R ^a   Miklos, D ^a   Shizuru, J ^a   Sheehan, K ^b   Lavori, P ^c   Negrin, R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

GVHD prophylaxis; mycophenolate mofetil; sirolimus; T regulatory cell

Indexed keywords

BUSULFAN; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LIVING DONOR; LOADING DRUG DOSE; LYMPHOMA; MENTAL DISEASE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRESCHOOL CHILD; PREVENTION STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUVA; REFRACTORY ANEMIA WITH EXCESS BLASTS; RELAPSE; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; WOUND HEALING IMPAIRMENT;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84859465951     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.104     Document Type: Article

References (51)

1. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181-1193. (Pubitemid 33026593)
2. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924-1929. (Pubitemid 34027865)
3. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108-3114. (Pubitemid 46482114)
4. Chao NJ. Pharmacology and use of immunosuppressive agents after hematopoietic cell transplantation. In: Thomas E, Blume K, Forman S (eds) Hematopoietic Cell Transplantation, 2nd edn. Blackwell: Malden, MA, 1999 pp 176-185.
5. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383-388. (Pubitemid 40542931)
6. Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490-500. (Pubitemid 47105386)
7. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130: 409-417. (Pubitemid 43899590)
8. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551-557. (Pubitemid 40862452)
9. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 47-55. (Pubitemid 40057993)
10. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112: 4425-4431.
11. Allison AC, Eugui EM. Mechanisms of action of mycophe-nolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80(2 Suppl): S181-S190. (Pubitemid 41552905)
12. Bestard O, Cruzado JM, Grinyo JM. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 2005; 37: 3729-3732. (Pubitemid 43015148)
13. Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005; 80(2 Suppl): S191-S200. (Pubitemid 41552906)
14. Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 2005; 80(2 Suppl): S211-S220. (Pubitemid 41552908)
15. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-65. (Pubitemid 28330537)
16. Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499-504. (Pubitemid 29114207)
17. Kiehl MG, Schafer-Eckart K, Kroger M, Bornhauser M, Basara N, Blau IW et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 2002; 34: 2922-2924. (Pubitemid 35304967)
18. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089-1093. (Pubitemid 40767198)
19. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 495-505. (Pubitemid 40862446)
20. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621-625. (Pubitemid 39341543)
21. Nguyen VH, Zeiser R, Negrin RS. Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 995-1009.
22. Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R et al. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2006; 12: 703-711. (Pubitemid 43899404)
23. Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3: 324-330. (Pubitemid 127530492)
24. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R et al. Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant 2011; 46: 192-199.
25. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic micro-angiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-575. (Pubitemid 41001631)
26. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783. (Pubitemid 18034278)
27. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
28. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
29. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005; 106: 4381-4388. (Pubitemid 41775952)
30. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
31. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008; 7: 458-462. (Pubitemid 351366473)
32. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-1046. (Pubitemid 28513384)
33. Kuppahally S, Al-Khaldi A, Weisshaar D, Valantine HA, Oyer P, Robbins RC et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6(5 Part 1): 986-992. (Pubitemid 44356648)
34. Champion L, Stern M, Israel-Biet D, Mamzer-Bruneel MF, Peraldi MN, Kreis H et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144: 505-509. (Pubitemid 46780673)
35. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001; 2: 1903-1917. (Pubitemid 33069483)
36. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042. (Pubitemid 29200856)
37. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D et al. Sirolimus in association with myco-phenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260. (Pubitemid 30238708)
38. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202. (Pubitemid 30446974)
39. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclospor-ine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280. (Pubitemid 32126112)
40. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059-1071. (Pubitemid 32378348)
41. Furlong T, Kiem HP, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008; 14: 531-537. (Pubitemid 351494744)
42. Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 2009; 15: 101-108.
43. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-399. (Pubitemid 43990654)
44. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009; 4: e5994.
45. Gatza E, Rogers CE, Clouthier SG, Lowler KP, Tawara I, Liu C et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112: 1515-1521.
46. Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+ Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007; 84: 31-39. (Pubitemid 47094638)
47. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291-1297. (Pubitemid 44232027)
48. Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 2007; 110: 1689-1697. (Pubitemid 47443988)
49. Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005; 78: 486-500. (Pubitemid 41698903)
50. Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol 2007; 47: 6-12. (Pubitemid 44973992)
51. Golconda MS, Valente JF, Bejarano P, Gilinsky N, First MR. Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients. Transplant Proc 1999; 31: 272-273. (Pubitemid 29127454)